Cytosorbents Corporation (CTSO)
Chart Events
Performance Outlook
| Previous Close | 9.71 |
| Open | 9.71 |
| Bid | 9.01 x 1000 |
| Ask | 9.69 x 1300 |
| Day's Range | 9.39 - 9.94 |
| 52 Week Range | 3.60 - 11.74 |
| Volume | 399,450 |
| Avg. Volume | 340,355 |
| Market Cap | 406.715M |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings Date | Nov 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.88 |
- PR Newswire
CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41st Annual Health Care Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present a brief overview of the Company's progress and outlook followed by a fireside chat with Joshua Jennings, MD, Managing Director, Senior Research Analyst, Equity Research at Cowen and Company. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your Cowen representative.
- PR Newswire
CytoSorbents 2021: Leadership and Growth in the "New Normal"
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan. Additional detail will be forthcoming in the Company's Q4 and Full Year 2020 earnings press release and Form 10-K, expected March 9, 2021.
- PR Newswire
CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will discuss the Company's progress and outlook with Danielle Antalffy, Managing Director, Medical Devices, Equity Research at SVB Leerink in a fireside chat format. Company management will also meet with investors in 1x1 meetings that are currently being scheduled, throughout the day. If interested, please contact your SVB Leerink representative.
